Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia
- PMID: 28445830
- DOI: 10.1016/j.biopha.2017.04.076
Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia
Abstract
Neoplasm cells from patients with chronic myeloid leukemia (CML) interact with stromal cells of the surrounding microenvironment. Bone marrow stromal cells (BMSCs) represent the main population in CML marrow stroma, which may play a key role in disease support and progression. Heme oxygenase-1 (HO-1) is a key enzyme of antioxidative metabolism that is associated with cell proliferation and resistance to apoptosis. We herein up-regulated HO-1 expression of BMSCs and evaluated whether BMSCs influenced K562 cells survival. BMSCs were isolated from the bone marrow of normal people and CML patients. Following co-culture of BMSCs and K562 cells, up-regulating HO-1 expression in bone marrow stromal cells increased the imatinib (IM) resistance of K562 cells, whereas the apoptosis of K562 cells was effectively promoted without BMSCs co-culture. The protection may be mediated by CXCL12 (stromal derived factors 1, SDF-1)/CXCR4 signaling. The CXCL12/CXCR4 interaction significantly enhanced the phosphorylation of AKT. As far as drug resistance was concerned, BMSCs counteracted the cytotoxic effect of IM administration in vitro, and they protected K562 cells from the apoptosis induced by kinase inhibitor IM. The regulated HO-1 expression of BMSCs provides a new putative target for CML therapy.
Keywords: Chronic myeloid leukemia; Heme oxygenase-1; Imatinib; Microenvironment; Resistance.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo.Mol Cancer Ther. 2014 May;13(5):1155-69. doi: 10.1158/1535-7163.MCT-13-0410. Epub 2014 Feb 6. Mol Cancer Ther. 2014. PMID: 24502926
-
Heme oxygenase-1 contributes to imatinib resistance by promoting autophagy in chronic myeloid leukemia through disrupting the mTOR signaling pathway.Biomed Pharmacother. 2016 Mar;78:30-38. doi: 10.1016/j.biopha.2015.12.029. Epub 2016 Jan 11. Biomed Pharmacother. 2016. PMID: 26898422
-
Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment.Mol Carcinog. 2017 Mar;56(3):863-876. doi: 10.1002/mc.22540. Epub 2016 Sep 22. Mol Carcinog. 2017. PMID: 27533597
-
Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia.Eur J Med Chem. 2017 Dec 15;142:163-178. doi: 10.1016/j.ejmech.2017.07.031. Epub 2017 Jul 20. Eur J Med Chem. 2017. PMID: 28756878 Review.
-
Role of CXCR4 in the pathogenesis of acute myeloid leukemia.Theranostics. 2013;3(1):34-9. doi: 10.7150/thno.5150. Epub 2013 Jan 13. Theranostics. 2013. PMID: 23382784 Free PMC article. Review.
Cited by
-
Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism.Cancer Biol Ther. 2018;19(9):825-834. doi: 10.1080/15384047.2018.1472188. Epub 2018 Jul 3. Cancer Biol Ther. 2018. PMID: 29969367 Free PMC article.
-
Circular RNA regulatory network reveals cell-cell crosstalk in acute myeloid leukemia extramedullary infiltration.J Transl Med. 2018 Dec 17;16(1):361. doi: 10.1186/s12967-018-1726-x. J Transl Med. 2018. PMID: 30558617 Free PMC article.
-
Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib-sensitivity in multiple myeloma via ERK/STAT3 axis.Aging (Albany NY). 2020 Apr 16;12(8):6611-6629. doi: 10.18632/aging.102996. Epub 2020 Apr 16. Aging (Albany NY). 2020. PMID: 32298237 Free PMC article.
-
The prognostic and therapeutic potential of HO-1 in leukemia and MDS.Cell Commun Signal. 2023 Mar 13;21(1):57. doi: 10.1186/s12964-023-01074-8. Cell Commun Signal. 2023. PMID: 36915102 Free PMC article. Review.
-
CAY10683 and imatinib have synergistic effects in overcoming imatinib resistance via HDAC2 inhibition in chronic myeloid leukemia.RSC Adv. 2020 Jan 3;10(2):828-844. doi: 10.1039/c9ra07971h. eCollection 2020 Jan 2. RSC Adv. 2020. PMID: 35494464 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials